Earnings Forecast Research on BioPharmX Corporation (BPMX)

BioPharmX Corporation has received $-0.09 as the consensus Earnings Estimate for the Quarter ending on Jan 2017 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.12 while the top line estimate is $-0.08 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 50.88%.

BioPharmX Corporation reported better than expected with a surprise EPS of 13.33% or $0.02 during its most recent quarterly earnings. The Actual EPS was $-0.13 compared to the Estimated EPS of $-0.15.

In the last quarter, BioPharmX Corporation reported Annual Earnings of $-0.13. Based on the filings, last years Annual Earnings was, $-0.86. In the last Quarter, BPMX reported a surprise Earnings per Share of 13.33% . The consensus estimate for current quarter is $-0.09 and for the current fiscal year, the estimate is $-0.54. For the Next fiscal year, the estimate is $-0.35 based on the consensus.

BioPharmX Corporation (NYSEMKT:BPMX) : On Tuesday heightened volatility was witnessed in BioPharmX Corporation (NYSEMKT:BPMX) which led to swings in the share price. The stock opened for trading at $0.48 and hit $0.51 on the upside , eventually ending the session at $0.486, with a gain of 1.25% or 0.006 points. The heightened volatility saw the trading volume jump to 1,790,796 shares. The 52-week high of the share price is $1.78 and the company has a market cap of $31 million. The 52-week low of the share price is at $0.1883 .

BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for womens health, dermatology and otolaryngology markets. The Companys product pipeline includes products in categories consists of prescription products, over-the-counter products and dietary supplements. Prescription products in development include molecular iodine pill for the treatment of breast pain associated with fibrocystic breast disease. OTC product pipeline includes a series of medicated bandages, nasal sprays and other products. Supplement product pipeline includes BioPharmXs breast health pill. Its product candidates include BPX03 a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia and BPX01 a non-lipophilic topical antibiotic for the treatment of acne. BioPharmX Corporation is headquartered in Menlo Park, California.


Share this post

Leave a Reply